Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Prostate Cancer

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 91 articles: HTML format Text format

Single Articles

September 2019
1. TAYLOR RA, Watt MJ
   Unsuspected Protumorigenic Signaling Role for the Oncometabolite GABA in Advanced Prostate Cancer.
   Cancer Res. 2019;79:4580-4581.
   PubMed     Text format     Abstract available
   
   
   
2. GENG C, Rajapakshe K, Shah SS, Shou J, et al
   Correction: Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer.
   Cancer Res. 2019;79:4552.
   PubMed     Text format    
   
   
   August 2019
3. CAI C, Han D, Chen S, Han W, et al
   ZBTB7A mediates the transcriptional repression activity of the androgen receptor in prostate cancer.
   Cancer Res. 2019 Aug 23. pii: 0008-5472.CAN-19-0815.
   PubMed     Text format     Abstract available
   
   
   
4. KAWAMURA N, Nimura K, Saga K, Ishibashi A, et al
   SF3B2-mediated RNA splicing drives human prostate cancer progression.
   Cancer Res. 2019 Aug 20. pii: 0008-5472.CAN-18-3965.
   PubMed     Text format     Abstract available
   
   
   July 2019
5. RUBENSTEIN CS, Gard JMC, Wang M, McGrath JE, et al
   Gene editing of alpha6 integrin inhibits muscle invasive networks and increases cell-cell biophysical properties in prostate cancer.
   Cancer Res. 2019 Jul 23. pii: 0008-5472.CAN-19-0868.
   PubMed     Text format     Abstract available
   
   
   
6. WU L, Shu X, Bao J, Guo X, et al
   Analysis of over 140,000 European descendants identifies genetically-predicted blood protein biomarkers associated with prostate cancer risk.
   Cancer Res. 2019 Jul 23. pii: 0008-5472.CAN-18-3997.
   PubMed     Text format     Abstract available
   
   
   June 2019
7. BOWEN C, Ostrowski MC, Leone G, Gelmann EP, et al
   Loss of PTEN Accelerates NKX3.1 Degradation to Promote Prostate Cancer Progression.
   Cancer Res. 2019 Jun 18. pii: 0008-5472.CAN-18-4110.
   PubMed     Text format     Abstract available
   
   
   
8. GAO Y, Chen L, Du Z, Gao W, et al
   Glutamate decarboxylase 65 signals through the androgen receptor to promote castration resistance in prostate cancer.
   Cancer Res. 2019 Jun 10. pii: 0008-5472.CAN-19-0700.
   PubMed     Text format     Abstract available
   
   
   May 2019
9. WU L, Wang J, Cai Q, Cavazos TB, et al
   Identification of novel susceptibility loci and genes for prostate cancer risk: A transcriptome-wide association study in over 140,000 European descendants.
   Cancer Res. 2019 May 17. pii: 0008-5472.CAN-18-3536.
   PubMed     Text format     Abstract available
   
   
   
10. GORDON JA, Noble JW, Midha A, Derakhshan F, et al
    Upregulation of Scavenger receptor B1 is required for steroidogenic and non-steroidogenic cholesterol metabolism in prostate cancer.
    Cancer Res. 2019 May 7. pii: 0008-5472.CAN-18-2529.
    PubMed     Text format     Abstract available
    
    
    
11. KAMINSKI L, Torrino S, Dufies M, Djabari Z, et al
    PGC-1alpha inhibits polyamine synthesis to suppress prostate cancer aggressiveness.
    Cancer Res. 2019 May 7. pii: 0008-5472.CAN-18-2043.
    PubMed     Text format     Abstract available
    
    
    April 2019
12. JIANG S, Wang X, Song D, Liu X, et al
    Cholesterol induces epithelial-to-mesenchymal transition of prostate cancer cells by suppressing degradation of EGFR through APMAP.
    Cancer Res. 2019 Apr 15. pii: 0008-5472.CAN-18-3295.
    PubMed     Text format     Abstract available
    
    
    
13. LI S, Fong KW, Gritsina G, Zhang A, et al
    Activation of MAPK signaling by CXCR7 leads to enzalutamide resistance in prostate cancer.
    Cancer Res. 2019 Apr 5. pii: 0008-5472.CAN-18-2812.
    PubMed     Text format     Abstract available
    
    
    February 2019
14. KUMAR R, Bhat TA, Walsh EM, Chaudhary AK, et al
    Cytochrome c-deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer.
    Cancer Res. 2019 Feb 14. pii: 0008-5472.CAN-18-2383.
    PubMed     Text format     Abstract available
    
    
    
15. WU L, Yi B, Wei S, Yao D, et al
    Loss of Foxp3 and Tsc1 Accelerate Prostate Cancer Progression through a Synergistic Transcriptional and Post-translational Regulation of c-MYC.
    Cancer Res. 2019 Feb 7. pii: 0008-5472.CAN-18-2049.
    PubMed     Text format     Abstract available
    
    
    January 2019
16. VUMMIDI GIRIDHAR P, Williams K, VonHandorf AP, Deford PL, et al
    Constant Degradation of the Androgen Receptor by MDM2 Conserves Prostate Cancer Stem Cell Integrity.
    Cancer Res. 2019 Jan 9. pii: 0008-5472.CAN-18-1753.
    PubMed     Text format     Abstract available
    
    
    November 2018
17. LO UG, Pong RC, Yang D, Gandee L, et al
    IFN-r-induced IFIT5 promotes epithelial-to-mesenchymal transition in prostate cancer via microRNA processing.
    Cancer Res. 2018 Nov 30. pii: 0008-5472.CAN-18-2207.
    PubMed     Text format     Abstract available
    
    
    
18. TRAVIS RC, Perez-Cornago A, Appleby PN, Albanes D, et al
    A collaborative analysis of individual participant data from 19 prospective studies assesses circulating vitamin D and prostate cancer risk.
    Cancer Res. 2018 Nov 13. pii: 0008-5472.CAN-18-2318.
    PubMed     Text format     Abstract available
    
    
    October 2018
19. 
    Retraction: Down-regulation of Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 Expression by Soy Isoflavones Enhances Prostate Cancer Radiotherapy In vitro and In vivo.
    Cancer Res. 2018;78:6028.
    PubMed     Text format    
    
    
    September 2018
20. PENFOLD L, Woods A, Muckett P, Nikitin AY, et al
    CAMKK2 promotes prostate cancer independently of AMPK via increased lipogenesis.
    Cancer Res. 2018 Sep 21. pii: 0008-5472.CAN-18-0585.
    PubMed     Text format     Abstract available
    
    
    
21. RUSSO JW, Gao C, Bhasin SS, Voznesensky OS, et al
    Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer.
    Cancer Res. 2018 Sep 21. pii: 0008-5472.CAN-18-0687.
    PubMed     Text format     Abstract available
    
    
    
22. 
    Retraction: Antitumor and Antimetastatic Activities of Docetaxel Are Enhanced by Genistein through Regulation of Osteoprotegerin/Receptor Activator of Nuclear Factor-kappaB (RANK)/RANK Ligand/MMP-9 Signaling in Prostate Cancer.
    Cancer Res. 2018;78:5475.
    PubMed     Text format    
    
    
    
23. 
    Retraction: Down-regulation of Androgen Receptor by 3,3'-Diindolylmethane Contributes to Inhibition of Cell Proliferation and Induction of Apoptosis in Both Hormone-Sensitive LNCaP and Insensitive C4-2B Prostate Cancer Cells.
    Cancer Res. 2018;78:5473.
    PubMed     Text format    
    
    
    
24. 
    Retraction: Inhibition of Angiogenesis and Invasion by 3,3'-Diindolylmethane Is Mediated by the Nuclear Factor-kappaB Downstream Target Genes MMP-9 and uPA that Regulated Bioavailability of Vascular Endothelial Growth Factor in Prostate Cancer.
    Cancer Res. 2018;78:5471.
    PubMed     Text format    
    
    
    
25. 
    Editor's Note: In vitro and In vivo Molecular Evidence for Better Therapeutic Efficacy of ABT-627 and Taxotere Combination in Prostate Cancer.
    Cancer Res. 2018;78:5465.
    PubMed     Text format    
    
    
    
26. JARATLERDSIRI W, Chan EKF, Gong T, Petersen DC, et al
    Whole Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naive, High-Risk Prostate Cancer.
    Cancer Res. 2018 Sep 14. pii: 0008-5472.CAN-18-0254.
    PubMed     Text format     Abstract available
    
    
    
27. GILLARD M, Javier R, Ji Y, Zheng SL, et al
    Elevated Stromal Inflammatory Mediators Promote Prostate Cancer Progression in African American Men.
    Cancer Res. 2018 Sep 4. pii: 0008-5472.CAN-17-3810.
    PubMed     Text format     Abstract available
    
    
    
28. 
    Correction: Cofilin Drives Cell-Invasive and Metastatic Responses to TGF-beta in Prostate Cancer.
    Cancer Res. 2018;78:5180.
    PubMed     Text format    
    
    
    August 2018
29. XIAO L, Tien JC, Vo J, Tan M, et al
    Epigenetic reprogramming with antisense oligonucleotides enhances the effectiveness of androgen receptor inhibition in castration-resistant prostate cancer.
    Cancer Res. 2018 Aug 22. pii: 0008-5472.CAN-18-0941.
    PubMed     Text format     Abstract available
    
    
    July 2018
30. CHEN S, Cai C, Sowalsky AG, Ye H, et al
    BMX-mediated regulation of multiple tyrosine kinases contributes to castration resistance in prostate cancer.
    Cancer Res. 2018 Jul 16. pii: 0008-5472.CAN-17-3615.
    PubMed     Text format     Abstract available
    
    
    
31. 
    Retraction: Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation.
    Cancer Res. 2018;78:4097.
    PubMed     Text format    
    
    
    
32. 
    Correction: Regulation of Minichromosome Maintenance Gene Family by MicroRNA-1296 and Genistein in Prostate Cancer.
    Cancer Res. 2018;78:3740.
    PubMed     Text format    
    
    
    June 2018
33. HOMPLAND T, Hole KH, Ragnum HB, Aarnes EK, et al
    Combined MR imaging of oxygen consumption and supply reveals tumor hypoxia and aggressiveness in prostate cancer patients.
    Cancer Res. 2018 Jun 26. pii: 0008-5472.CAN-17-3806.
    PubMed     Text format     Abstract available
    
    
    
34. KOLIJN K, Verhoef EI, Smid M, Bottcher R, et al
    Epithelial-mesenchymal transition in human prostate cancer demonstrates enhanced immune evasion marked by IDO1 expression.
    Cancer Res. 2018 Jun 19. pii: 0008-5472.CAN-17-3752.
    PubMed     Text format     Abstract available
    
    
    
35. 
    Correction: miRNA-708 Control of CD44(+) Prostate Cancer-Initiating Cells.
    Cancer Res. 2018;78:3404.
    PubMed     Text format    
    
    
    
36. 
    Retraction: Demethylation-Linked Activation of Urokinase Plasminogen Activator Is Involved in Progression of Prostate Cancer.
    Cancer Res. 2018;78:3397.
    PubMed     Text format    
    
    
    
37. LIU J, Chen G, Liu Z, Liu S, et al
    Aberrant FGFR tyrosine kinase signaling enhances the Warburg effect by reprogramming LDH isoform expression and activity in prostate cancer.
    Cancer Res. 2018 Jun 11. pii: 0008-5472.CAN-17-3226.
    PubMed     Text format     Abstract available
    
    
    
38. LI X, Wang X, Song W, Xu H, et al
    Oncogenic properties of NEAT1 in prostate cancer cells depend on the CDC5L-AGRN transcriptional regulation circuit.
    Cancer Res. 2018 Jun 5. pii: 0008-5472.CAN-18-0688.
    PubMed     Text format     Abstract available
    
    
    May 2018
39. LU X, Pan X, Wu CJ, Zhao D, et al
    An in vivo screen identifies PYGO2 as a driver for metastatic prostate cancer.
    Cancer Res. 2018 May 16. pii: 0008-5472.CAN-17-3564.
    PubMed     Text format     Abstract available
    
    
    
40. MOSES MA, Kim YS, Rivera-Marquez GM, Oshima N, et al
    Targeting the Hsp40/Hsp70 chaperone axis as a novel strategy to treat castration-resistant prostate cancer.
    Cancer Res. 2018 May 15. pii: 0008-5472.CAN-17-3728.
    PubMed     Text format     Abstract available
    
    
    April 2018
41. ZHANG Z, Cheng L, Li J, Farah E, et al
    Inhibition of the Wnt/beta-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate cancer.
    Cancer Res. 2018 Apr 26. pii: 0008-5472.CAN-17-3006.
    PubMed     Text format     Abstract available
    
    
    March 2018
42. DAS SK, Pradhan AK, Bhoopathi P, Talukdar S, et al
    The MDA-9/Syntenin/IGF-1R/STAT3 axis directs prostate cancer invasion.
    Cancer Res. 2018 Mar 23. pii: 0008-5472.CAN-17-2992.
    PubMed     Text format     Abstract available
    
    
    
43. YU G, Cheng CJ, Lin SC, Lee YC, et al
    Organelle-derived acetyl-CoA promotes prostate cancer cell survival, migration, and metastasis via activation of calmodulin kinase II.
    Cancer Res. 2018 Mar 13. pii: 0008-5472.CAN-17-2392.
    PubMed     Text format     Abstract available
    
    
    
44. YU-LEE LY, Yu G, Lee YC, Lin SC, et al
    Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGFbetaRIII-p38MAPK-pS249/T252RB pathway.
    Cancer Res. 2018 Mar 7. pii: 0008-5472.CAN-17-1051.
    PubMed     Text format     Abstract available
    
    
    February 2018
45. CI X, Hao J, Dong X, Choi SYC, et al
    Heterochromatin protein 1alpha mediates development and aggressiveness of neuroendocrine prostate cancer.
    Cancer Res. 2018 Feb 27. pii: 0008-5472.CAN-17-3677.
    PubMed     Text format     Abstract available
    
    
    
46. SORRENTINO C, Ciummo SL, Cipollone G, Caputo S, et al
    Interleukin-30/IL-27p28 shapes prostate cancer stem-like cell behavior and is critical for tumor onset and metastasization.
    Cancer Res. 2018 Feb 27. pii: 0008-5472.CAN-17-3117.
    PubMed     Text format     Abstract available
    
    
    
47. LACHANCE J, Berens AJ, Hansen MEB, Teng AK, et al
    Genetic hitchhiking and population bottlenecks contribute to prostate cancer disparities in men of African descent.
    Cancer Res. 2018 Feb 8. pii: 0008-5472.CAN-17-1550.
    PubMed     Text format     Abstract available
    
    
    
48. XIAO L, Wang Y, Xu K, Hu H, et al
    Nuclear receptor LRH-1 functions to promote castration-resistant growth of prostate cancer via its promotion of intratumoral androgen biosynthesis.
    Cancer Res. 2018 Feb 8. pii: 0008-5472.CAN-17-2341.
    PubMed     Text format     Abstract available
    
    
    
49. JUNG Y, Cackowski FC, Yumoto K, Decker A, et al
    CXCL12gamma Promotes Development of Metastatic Castration Resistant Prostate Cancer by Induction of Cancer Stem Cell and Neuroendocrine Phenotypes.
    Cancer Res. 2018 Feb 5. pii: 0008-5472.CAN-17-2332.
    PubMed     Text format     Abstract available
    
    
    
50. BHAGIRATH D, Yang TL, Bucay N, Sekhon K, et al
    MicroRNA-1246 is an exosomal biomarker for aggressive prostate cancer.
    Cancer Res. 2018 Feb 1. pii: 0008-5472.CAN-17-2069.
    PubMed     Text format     Abstract available
    
    
    January 2018
51. MCCLINCH K, A Avelar R, Callejas D, Izadmehr S, et al
    Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer.
    Cancer Res. 2018 Jan 22. pii: 0008-5472.CAN-17-0123.
    PubMed     Text format     Abstract available
    
    
    
52. LU Y, Hu Z, Mangala LS, Stine ZE, et al
    MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.
    Cancer Res. 2018;78:64-74.
    PubMed     Text format     Abstract available
    
    
    
53. ROSSNAGL S, Ghura H, Groth C, Altrock E, et al
    A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow.
    Cancer Res. 2018;78:129-142.
    PubMed     Text format     Abstract available
    
    
    December 2017
54. COUTURE F, Sabbagh R, Kwiatkowska A, Desjardins R, et al
    PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer.
    Cancer Res. 2017;77:6863-6879.
    PubMed     Text format     Abstract available
    
    
    
55. HORNING AM, Wang Y, Lin CK, Louie AD, et al
    Single-cell RNA-seq reveals a subpopulation of prostate cancer cells with enhanced cell cycle-related transcription and attenuated androgen response.
    Cancer Res. 2017 Dec 12. pii: 0008-5472.CAN-17-1924.
    PubMed     Text format     Abstract available
    
    
    
56. YOU S, Freeman MR
    A Systems Approach to Prostate Cancer Classification-Response.
    Cancer Res. 2017 Dec 6. pii: 0008-5472.CAN-17-0239.
    PubMed     Text format    
    
    
    
57. THYSELL E, Ylitalo EB, Jernberg E, Bergh A, et al
    A Systems Approach to Prostate Cancer Classification-Letter.
    Cancer Res. 2017 Dec 6. pii: 0008-5472.CAN-16-3231.
    PubMed     Text format    
    
    
    
58. YANG Y, Blee AM, Wang D, An J, et al
    Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.
    Cancer Res. 2017;77:6524-6537.
    PubMed     Text format     Abstract available
    
    
    November 2017
59. MARTIN-MARTIN N, Zabala-Letona A, Fernandez-Ruiz S, Arreal L, et al
    PPARdelta elicits ligand-independent repression of Trefoil Factor Family to limit prostate cancer growth.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0908.
    PubMed     Text format     Abstract available
    
    
    
60. EMERSON MA, Banegas MP, Chawla N, Achacoso N, et al
    Disparities in Prostate, Lung, Breast, and Colorectal Cancer Survival and Comorbidity Status among Urban American Indians and Alaskan Natives.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0429.
    PubMed     Text format     Abstract available
    
    
    
61. ALEXANDER J, Kendall J, McIndoo J, Rodgers L, et al
    Utility of single cell genomics in diagnostic evaluation of prostate cancer.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1138.
    PubMed     Text format     Abstract available
    
    
    
62. MURPHY SJ, Kosari F, Karnes RJ, Nasir A, et al
    Retention of Interstitial Genes between TMPRSS2 and ERG Is Associated with Low-Risk Prostate Cancer.
    Cancer Res. 2017;77:6157-6167.
    PubMed     Text format     Abstract available
    
    
    October 2017
63. KIM S, Alsaidan OA, Goodwin O, Li Q, et al
    Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression.
    Cancer Res. 2017 Oct 16. pii: canres.0981.2017.
    PubMed     Text format     Abstract available
    
    
    
64. PONNUSAMY S, Coss CC, Thiyagarajan T, Watts K, et al
    Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer.
    Cancer Res. 2017 Oct 4. pii: canres.0976.2017.
    PubMed     Text format     Abstract available
    
    
    
65. DAMASCHKE NA, Yang B, Bhusari S, Avilla M, et al
    Loss of Igf2 Gene Imprinting in Murine Prostate Promotes Widespread Neoplastic Growth.
    Cancer Res. 2017;77:5236-5247.
    PubMed     Text format     Abstract available
    
    
    September 2017
66. SAN MARTIN R, Pathak R, Jain A, Jung SY, et al
    Tenascin-C and integrin alpha9 mediate interactions of prostate cancer with the bone microenvironment.
    Cancer Res. 2017 Sep 15. pii: canres.0064.2017.
    PubMed     Text format     Abstract available
    
    
    
67. LIANG Y, Ahmed M, Guo H, Soares F, et al
    LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.
    Cancer Res. 2017 Sep 15. pii: canres.0496.2017.
    PubMed     Text format     Abstract available
    
    
    August 2017
68. WANG L, Song G, Zhang X, Feng T, et al
    PADI2-mediated citrullination promotes prostate cancer progression.
    Cancer Res. 2017 Aug 17. pii: canres.0150.2017.
    PubMed     Text format     Abstract available
    
    
    
69. JIN L, Garcia J, Chan E, de la Cruz C, et al
    Therapeutic targeting of the CBP/p300 bromodomain blocks the growth of castration-resistant prostate cancer.
    Cancer Res. 2017 Aug 17. pii: canres.0314.2017.
    PubMed     Text format     Abstract available
    
    
    
70. SCHER HI, Graf RP, Schreiber N, McLaughlin B, et al
    Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.
    Cancer Res. 2017 Aug 17. pii: canres.1353.2017.
    PubMed     Text format     Abstract available
    
    
    
71. VAN ETTEN JL, Nyquist M, Li Y, Yang R, et al
    Targeting a single alternative polyadenylation site coordinately blocks expression of androgen receptor mRNA splice variants in prostate cancer.
    Cancer Res. 2017 Aug 15. pii: canres.0320.2017.
    PubMed     Text format     Abstract available
    
    
    
72. VAN ETTEN JL, Nyquist M, Li Y, Yang R, et al
    Targeting a Single Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor mRNA Splice Variants in Prostate Cancer.
    Cancer Res. 2017 Aug 15. doi: 10.1158/0008-5472.CAN-17-0320.
    PubMed     Text format     Abstract available
    
    
    
73. BAINOR AJ, Deng FM, Wang Y, Lee P, et al
    Chromatin-associated protein SIN3B prevents prostate cancer progression by inducing senescence.
    Cancer Res. 2017 Aug 14. pii: canres.3410.2016.
    PubMed     Text format     Abstract available
    
    
    July 2017
74. YIN Y, Li R, Xu K, Ding S, et al
    Androgen receptor variants mediate DNA repair after prostate cancer irradiation.
    Cancer Res. 2017 Jul 28. pii: canres.0164.2017.
    PubMed     Text format     Abstract available
    
    
    
75. 
    Correction: MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer.
    Cancer Res. 2017;77:3961.
    PubMed     Text format    
    
    
    
76. SAHA A, Ahn S, Blando J, Su F, et al
    Proinflammatory CXCL12-CXCR4/CXCR7 signaling axis drives Myc-induced prostate cancer in obese mice.
    Cancer Res. 2017 Jul 7. pii: canres.0284.2017.
    PubMed     Text format     Abstract available
    
    
    June 2017
77. LOVERIDGE CJ, Mui EJ, Patel R, Tan EH, et al
    Increased T-cell Infiltration Elicited by Erk5 Deletion in a Pten-Deficient Mouse Model of Prostate Carcinogenesis.
    Cancer Res. 2017;77:3158-3168.
    PubMed     Text format     Abstract available
    
    
    
78. WANG Y, Wang J, Zhang L, Karatas OF, et al
    RGS12 is a novel tumor suppressor gene in African American prostate cancer that represses AKT and MNX1 expression.
    Cancer Res. 2017 Jun 13. pii: canres.0669.2017.
    PubMed     Text format     Abstract available
    
    
    May 2017
79. 
    Correction: Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4-O-Glycan to Cancer Cells.
    Cancer Res. 2017;77:2772.
    PubMed     Text format    
    
    
    
80. MALEK R, Gajula RP, Williams RD, Nghiem B, et al
    TWIST1-WDR5-Hottip regulates Hoxa9 chromatin to facilitate prostate cancer metastasis.
    Cancer Res. 2017 May 8. pii: canres.2797.2016.
    PubMed     Text format     Abstract available
    
    
    
81. PALTOGLOU S, Das R, Townley SL, Hickey T, et al
    Novel androgen receptor co-regulator GRHL2 exerts both oncogenic and anti-metastatic functions in prostate cancer.
    Cancer Res. 2017 May 4. pii: canres.1616.2016.
    PubMed     Text format     Abstract available
    
    
    
82. IBRAHIM-HASHIM A, Robertson-Tessi M, Enriquez-Navas PM, Damaghi M, et al
    Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution.
    Cancer Res. 2017;77:2242-2254.
    PubMed     Text format     Abstract available
    
    
    April 2017
83. KOLONIN MG, Sergeeva A, Staquicini DI, Smith TL, et al
    Interaction between tumor cell surface receptor RAGE and proteinase 3 mediates prostate cancer metastasis to bone.
    Cancer Res. 2017 Apr 20. pii: canres.0708.2016.
    PubMed     Text format     Abstract available
    
    
    
84. WEN D, Peng Y, Lin F, Singh RK, et al
    Micellar delivery of miR-34a modulator rubone and paclitaxel in resistant prostate cancer.
    Cancer Res. 2017 Apr 20. pii: canres.2355.2016.
    PubMed     Text format     Abstract available
    
    
    
85. CHEN HY, Larson PEZ, Bok RA, von Morze C, et al
    Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion.
    Cancer Res. 2017 Apr 20. pii: canres.2083.2016.
    PubMed     Text format     Abstract available
    
    
    March 2017
86. KURMIS AA, Yang F, Welch TR, Nickols NG, et al
    A pyrrole-imidazole polyamide is active against enzalutamide-resistant prostate cancer.
    Cancer Res. 2017 Mar 30. pii: canres.2503.2016.
    PubMed     Text format     Abstract available
    
    
    
87. WEI X, Xu Y, Xu FF, Chaiswing L, et al
    RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells.
    Cancer Res. 2017;77:1345-1356.
    PubMed     Text format     Abstract available
    
    
    
88. OH DY, Cham J, Zhang L, Fong G, et al
    Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
    Cancer Res. 2017;77:1322-1330.
    PubMed     Text format     Abstract available
    
    
    February 2017
89. MANZO T, Sturmheit T, Basso V, Petrozziello E, et al
    T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFalpha Expression and Empower Adoptive Cell Therapy for Solid Tumors.
    Cancer Res. 2017;77:658-671.
    PubMed     Text format     Abstract available
    
    
    January 2017
90. BERNICHTEIN S, Pigat N, Barry Delongchamps N, Boutillon F, et al
    Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation.
    Cancer Res. 2017;77:355-365.
    PubMed     Text format     Abstract available
    
    
    April 2016
91. LINDQUIST KJ, Paris PL, Hoffmann TJ, Cardin NJ, et al
    Mutational Landscape of Aggressive Prostate Tumors in African American Men.
    Cancer Res. 2016;76:1860-8.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: